Tourette syndrome
Conditions
Interventions
FC group:Functional connectivity-guided rTMS targeting was used with 1 Hz stimulation administered twice daily (morning and afternoon) for two consecutive weeks. Each session involved 1,800 pulses at
Traditional group:Traditional Localization Group Stimulation Coordinates: The stimulation site is the left supplementary motor area (SMA), determined according to relevant literature as being located
Sponsors
the Affiliated Hospital of Hangzhou Normal University
Eligibility
Sex/Gender
All
Age
8 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1.Age: 8-18 years; 2.Diagnosis of Tourette syndrome (based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition [DSM-5]); 3.Wechsler Intelligence Scale score above 80; 4.Yale Global Tic Severity Scale (YGTSS) total motor + vocal tic score >= 20; 5.Minimal comorbidities, with no significant psychiatric symptoms; 6.At least six months of regular pharmacotherapy with unsatisfactory outcomes; 7.Able to accept TMS therapy, and willing to participate in the study treatment and follow-up; 8.If the specialist diagnoses that the participant has a large tic amplitude and cannot cooperate with the MRI scan and therefore needs to be sedated, the participant and his/her guardian agree to undergo the MRI scan under sedation.
Exclusion criteria
Exclusion criteria: 1.Patients with learning disabilities (e.g., intellectual disability, developmental delay, speech delay) or any contraindications to chloral hydrate; 2.Those who do not meet the inclusion criteria specified by the clinical research protocol; 3.Those with severe organic diseases of the cardiovascular, hepatic, renal, hematopoietic, or nervous systems (e.g., chronic nephritis, hepatitis, congenital heart disease, chorea, subacute encephalitis, etc.); 4.Those presenting with conduct disorder, pervasive developmental disorder, intellectual disability, mood disorders, schizophrenia, or other mental health issues; 5.Those who fail to complete the full course of treatment, making it impossible to assess efficacy or whose incomplete data otherwise affect efficacy or safety evaluations.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| YGTSS (Yale Global Tic Severity Scale);PUTS (Premonitory Urge for Tics Scale); | — |
Secondary
| Measure | Time frame |
|---|---|
| MRI related metrics; | — |
Countries
China
Contacts
Public ContactZang Yufeng
the Affiliated Hospital of Hangzhou Normal University
Outcome results
None listed